



Correction to: Complement in ischaemia–reperfusion injury and transplantation

Mark C. Howard¹ · Christopher L. Nauser¹ · Conrad A. Farrar¹ · Steven H. Sacks¹

Published online: 18 March 2022

© The Author(s) 2022

Correction to: *Seminars in Immunopathology* (2021) 43:789–797
<https://doi.org/10.1007/s00281-021-00896-3>

The order of Reference 78–85 were incorrect. Here is the correct information:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

78. Tatapudi VS, Montgomery RA (2019) Therapeutic modulation of the complement system in kidney transplantation: clinical indications and emerging drug leads. *Front Immunol* 10:2306
79. C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection. <https://ClinicalTrials.gov/show/NCT02936479>
80. Amyndas. <https://www.amyndas.com/researchfocus>. Accessed 20/09/21
81. Hillmen P, Szer J, Weitz I, Roth A, Hochsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro C, Nishimori H, Tan L, Hamdani M, Deschatelets P, Francois C, Grossi F, Ajayi T, Risitano A, de la Tour RP (2021) Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. *N Engl J Med* 384:1028–1037
82. Jaffe GJ, Sahni J, Fauser S, Geary RS, Schneider E, McCaleb M (2020) Development of IONIS-FB-LRx to treat geographic atrophy associated with AMD. *Investig Ophthalmol Vis Sci* 61:4305
83. Risitano AM, Kulasekararaj AG, Lee JW, Maciejewski JP, Notaro R, Brodsky R, Huang M, Geffner M, Browett P (2020) Danicoplan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. *Haematologica*. Online ahead of print
84. Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S (2020) Rationale for targeting complement in COVID-19. *EMBO Mol Med* 12:e12642
85. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, Paranjpe I, Somani S, Richter F, Miotto R, Lala A, Kia A, Timsina P, Li L, Freeman R, Chen R, Narula J, Just AC, Horowitz C, Fayad Z, Cordon-Cardo C, Schadt E, Levin MA, Reich DL, Fuster V, Murphy B, He JC, Charney AW, Bottinger EP, Glicksberg BS, Coca SG, Nadkarni GN, Mount Sinai CIC (2021) AKI in hospitalized patients with COVID-19. *J Am Soc Nephrol* 32:151–160

The original article can be found online at <https://doi.org/10.1007/s00281-021-00896-3>.

✉ Mark C. Howard
mark.howard@kcl.ac.uk

¹ Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, 5th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.